Valeant Pharma (VRX) Reports Q1 Revenues Above Estimates; Boosts FY18 Revenue & EBITDA Outlook

Valeant Pharmaceuticals (VRX): 'A Turnaround For The Ages' - Cantor Fitzgerald

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $25 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q1 beat and raise.

"We think a greater appreciation for Valeant's solid execution and future growth prospects should drive upwards earnings revisions as well as multiple expansion in 2019+,"... More

Valeant Pharma (VRX) Confirms Name Change to Bausch Health (BHC)

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that the Company will change its name to Bausch Health Companies Inc., effective in July 2018.

"Becoming Bausch Health Companies is a major step forward in our transformation," said Joseph C. Papa, chairman and CEO, Valeant. "The Bausch name embodies the rich history of innovation, fortitude and dedication to patient health dating back to when J.J. Bausch opened his first optical goods shop more than 165 years ago. These qualities form the foundation of who we are today as we continue to build an innovative company... More

Valeant Pharma (VRX) to Change Name to Bausch Health (BHC) - WSJ

Valeant Pharma (NYSE: VRX) will change its name to Bausch Health, the Wall Street Journal reported.

The name change is expected to be announced Tuesday with earnings.

The company will also change its stock symbol to BHC.

We think this... More

Stocks with Implied Volatility Movement

Valeant Pharma (NYSE: VRX) implied volatility index movement increasing vs 30D HV

Valeant Pharma (VRX) call put ratio 2.66 calls to 1 put with focus on May weekly 19 and 19.50 calls into Q1 and outlook

Valeant Pharma (NYSE: VRX) call put ratio 2.66 calls to 1 put with focus on May weekly 19 and 19.50 calls into Q1 and outlook

Valeant Pharma (VRX) option implied volatility elevated into Q1 and outlook

Valeant Pharma (NYSE: VRX) May weekly call option implied volatility is at 117, May is at 80, June is at 55; compared to its 52-week range of 41 to 87 into the expected release of Q1 results before the open on May 8.

Valeant's (VRX) Salix Announces FDA Approval For PLENVU

Valeant Pharmaceuticals (NYSE: VRX) subsidary Salix Pharmaceuticals, Ltd. and its partner Norgine B.V. announced today that the U.S. Food and Drug Administration (FDA) has approved PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), a lower-volume (1L) polyethylene glycol based (PEG) bowel preparation.

Colorectal cancer is the third leading cause of cancer-related deaths in women and the second leading cause in men in the United States. The American Cancer Society estimates that there are approximately 97,000 new cases of colon cancer and... More